pHOXBIO’s nasal spray prevents SARS-CoV-2 infection in Phase II/III trial
Nearly 13.1% of subjects in the pHOXWELL arm were tested positive for Covid-19 versus 34.5%...
News
PathAI and Summit Clinical offer new solution for NASH trials
The companies will address high costs for site activation and enrolment barriers linked to NASH...
Gilead’s Veklury reduces hospitalisation risk in Phase III Covid-19 trial
By day 28, subjects receiving Velkury had an 81% reduction in risk of medical visits...
Trialbee collaborates with Castor to boost access to trials
The partners will facilitate diversified participation and improve health equity for decentralised and hybrid clinical...
Feinstein starts third Moderna Covid vaccine trial for transplant patients
The trial plans to enrol 240 subjects to evaluate immune antibody response 28 days following...
Ampio obtains DCGI approval for Phase II Covid-19 trial of inhaled drug
In the trial, inhaled Ampion will be used to treat patients with respiratory distress associated with Covid-19.
Rhizen doses first subject in Phase II Covid-19 oral drug trial in India
The Phase II trial will enrol up to 204 Covid-19 patients at across 12 study centres in India.
Roche’s Tecentriq shows benefits in Phase III early-stage lung cancer trial
In the trial, tecentriq demonstrated safety profile consistent to known data, without any new safety signals identified.
Gritstone starts Phase I dosing of second-gen mRNA Covid-19 vaccine
The trial will test the safety, tolerability and immunogenicity of two dose levels of the vaccine given as a booster to Vaxzevria.
Landos and Icahn School of Medicine partner for Crohn’s disease drug trial
The Phase II trial will assess the efficacy, safety and mechanisms of omilancor in nearly 40 moderate-to-severe CD patients.
Eiger obtains DSMB approval to progress Phase III Covid-19 therapy trial
The recommendation follows an interim futility analysis conducted by the panel on a sample size of 453 subjects.
